chain urokinase-type plasminogen activator (rscu-PA) fused to the murine monoclonal antibody 59D8, which is directed against an aminoterminal epitope in the 83-chain of fibrin,3 was found to have a sixfold higher thrombolytic potency than rscu-PA. 16 Chemical complexes of the monoclonal antibody MA-15C54 directed against a neoantigenic epitope in fragment D-dimer of human cross-linked fibrin, and rscu-PA had a sixfold enhanced potency in venous thrombosis models in rabbits14 and baboons.15 In addition, the recombinant chimeric plasminogen activator rscu-PA-32k/MA-15C5Hu, which consists of humanized MA-15C5 (MA-15C5Hu) and a 32-kd single-chain urokinase-type plasminogen activator comprising amino acids Leu144-Leu41' (scu-PA32k),17 had an 11-fold higher thrombolytic potency than rscu-PA in rabbits with a jugular vein clot prepared from human plasma.18
Clot targeting of thrombolytic agents with antifibrin antibodies may be hampered by a low density of the specific epitopes at the clot surface or by changing binding profiles during clot maturation or lysis. 19 Therefore, in the present in vivo study in hamsters and rabbits, we determined the clot-binding and the plasminogen activator-targeting properties of another fibrin-specific monoclonal antibody, MA-12B3, which is directed against an epitope localized in a 27-amino-acid region (Lys78-Asn104) spanning the carboxy terminal end of fragment E and the amino terminal end of fragment D in the a-chain of fibrin. 20 We hypothesized that this epitope would be initially exposed at the clot surface and remain associated with the core of the thrombus during plasmin-mediated fibrin digestion. To was mixed with pooled human plasma to which 10 NIH units/mL of thrombin (Sigma, St. Louis, Mo.) and 34 mM CaCl2 were added. The mixture was then aspirated in the syringe, and the clot was aged for 60 minutes. The syringe was inserted into an extracorporeal loop connecting the femoral artery with the femoral vein of a rabbit. Further incorporation of fibrinogen into the clot was prevented with heparin (Liquemin, F. Hoffinann-La Roche, Basel, Switzerland) given as a bolus of 300 IU/kg, followed by an intravenous infusion of 60 IU kg.* hr-1 over 6 hours. Adhesion of platelets to the clot was prevented by injection of 7.5 mg/kg ridogrel, a combined thromboxane synthase inhibitor/endoperoxide receptor antagonist27 (Janssen Research Foundation, Beerse, Belgium), 30 minutes before the start of the experiment.`2I-Labeled MA-12B3 or MA-15C5 (7.5 jig per rabbit representing 25 ,pCi "2I) was injected via a marginal ear vein. In the first series of experiments, the binding of antibody to intact human plasma clots was determined by measuring the radioisotope bound to the clot, which was recovered 6 hours after the injection of labeled antibody. In all subsequent experiments, the time course of the binding of`MI-labeled antibody to the clot in the syringe was monitored with a scintillation crystal (Model 3 M.5-3, Bicron, Newbury, Ohio) connected to a multichannel photomultiplier (Model S-100, Canberra, Meridan, Conn.). The`2I incorporated in the plasma clot as MI-labeled fibrinogen to allow determination of the extent of digestion represented approximately 0.2% of the amount of the injected`MI-labeled antibody and <10% of the 1"I-lab-ed --antibody bound to the clot.
Rabbit plasma clots that do not cross-react with the human fibrin-specific antibodies were prepared in the same way as the human plasma clots and were incorporated in a second syringe in the same extracorporeal loop. The radioactivity that bound to the rabbit plasma clots was subtracted as aspecific binding from the radioactivity that bound to the human plasma clots. The number of clot-bound antibody molecules was calculated from the amount of radioactivity that specifically bound to the human plasma clot and from the specific radioactivities of the`MI-labeled antibody preparations. Thrombolysis of 125I-Fibrin-Labeled Human Plasma
Clots in a Hamster Pulmonary Embolism Model
The thrombolytic potencies of rscu-PA/MA-12B3, rscu-PA/MA-15C5, rscu-PA, and rt-PA were determined in hamsters with an experimental pulmonary embolus consisting of a human plasma clot injected via the jugular vein, as described previously.32 Thrombolytic agents were infused intravenously over 60 minutes, and lysis was measured 30 minutes after the end of the infusion as the difference between the radioactivity initially incorporated in the clot and the residual radioactivity in the lungs and the heart. Alternatively, the release of the radioactivity from the clot was measured continuously as was described earlier for the rabbit jugular vein thrombosis model.33 Blood samples were collected before the start of the infusion at 60 minutes (for determination of u-PA-related antigen) and at 90 minutes (for determination of residual fibrinogen and a2-antiplasmin levels).
Analysis of the Thrombolysis Data
At the end of the thrombolysis experiments in rabbits, the clot was removed from the jugular vein, and the extent of thrombolysis was calculated from the disappearance of radioactivity from the clot. At the end of the thrombolysis experiments in hamsters, the lungs were removed, and the residual radioactivity in the lungs of the hamsters was measured. The extent of thrombolysis was derived from the disappearance of radioactivity from the lungs. The relative thrombolytic potency and specific thrombolytic activity of the compounds in hamsters and rabbits were determined from the dose-response curves derived by fitting of the individual dose-response data (percent lysis versus dose in mg/kg or percent lysis versus steady-state u-PArelated antigen in ug/mL) with an exponentially transformed sigmoidal function: lOOc Y=1 +e -a(ex-eb) using the statistical program GRAFIT (Erithacus Ltd., Middlesex, UK). Mean±SEM values of the parameters c (maximal lysis in percent), b (dose in mg/kg or in ,ug/mL plasma antigen at which the rate of lysis is maximal), and z=(ac/4) * e' (maximal rate of lysis, expressed as percent lysis per mg/kg compound infused or as percent lysis per /g/mL plasma antigen) were determined. 34 The significance of the differences between these parameters was determined using Student's t test.
To determine the time course of thrombolysis in hamsters, the disappearance of radioactivity from the lungs was monitored continuously by external radioisotope scanning over the thorax.32'33 The rates of thrombolysis obtained with the different compounds in hamsters were determined by fitting the individual data (percent lysis versus time in minutes) with an exponentially transformed sigmoidal function: c Y=1 +e(a-bt) using the statistical program GRAFIT as described above for determining the clot-binding parameters. Table 3 . Clot lysis measured 30 minutes after the end of the infusion of saline into six control animals was 8± 1% (mean± SEM; n=6). Fibrinogen and a2-antiplasmin levels at the end of the experiment were 110±10% and 96±4% of the baseline values, respectively. With rscu-PA/MA-12B3 at tThe plasma clearance (Cl p) was calculated as the ratio of the infusion rate (1£g/min) and the steady-state plasma concentration of antigen (1g/mL).
190±62% and 86±20% lysis per ug/mL steady-state plasma u-PA-related antigen, respectively) and was 3.1-fold higher (p=0.025) than for rscu-PA (61+9% lysis per ug/mL u-PA antigen). The maximal rate of lysis was obtained at a steady-state plasma u-PA antigen concentration of 0.12±0.03 ,ug/mL of rscu-PA/MA-12B3 compared with 0.39±0.07 ,ug/mL of rscu-PA/MA-15C5 (p=0.003) and 1.1±0.08 ,ug/mL of rscu-PA (p<O.OOl). Pharmacokinetics of rscu-PA/MA-12B3 and rscu-PA/MA-JSCS in Rabbits Plasma clearances derived from the steady-state plasma u-PA antigen levels at the end of the infusion were 3.8 mL * min1 for rscu-PA/MA-12B3, 2.6 mL* min' for rscu-PA/MA-15C5, and 22 mL* min1 for rscu-PA ( summarized in Table 6 . With rscu-PA/MA-12B3, the maximal rate of lysis was 1.4-fold lower (p=NS) than for rscu-PA/MA-15C5 (z values of 2,500±440% and 3,600±640% lysis per mg u-PA/kg, respectively), 42-fold higher (p<0.001) than for rscu-PA (z=60±8% lysis per mg u-PA/kg), and 6.6-fold higher (p<0.001) than for rt-PA (z=380±66% lysis per mg t-PA). The maximal rate of lysis was obtained at similar doses of rscu-PA/MA-12B3 and of rscu-PA/MA-15C5 (0.007 mg u-PA/kg of both rscu-PA/MA-12B3 and rscu-PA/MA-15C5) compared with 0.51±0.09 mg u-PA/kg of rscu-PA (p<0.001) and to 0.058±0.006 mg t-PA/kg of rt-PA (p<0.001). The dose-response data for rscu-PA/MA-12B3, rscu-PA/ MA-15C5, and rscu-PA are illustrated in Figure 2 . The dose-response data expressed as percent lysis per ,ug/mL steady-state plasma u-PA-related antigen were also fitted with the exponentially transformed sigmoidal function as described previously,33 yielding the corresponding c', z', and b' values for specific thrombolytic activity (Table 6 ). With rscu-PA/MA-12B3 the maximal rate of lysis was threefold lower (p=0.044) than with rscu-PA/MA-15C5 (z' values of 660±150% and 1,900±610% lysis per ,ug/mL steady-state plasma u-PArelated antigen, respectively), was 11-fold higher (p<O.OOI) than for rscu-PA (65+7% lysis per ,g/mL u-PA antigen), and was similar to that for rt-PA (700±150% lysis per ,ug/mL t-PA antigen). The doseresponse data for rscu-PA/MA-12B3, rscu-PA/MA-15C5, and rscu-PA are illustrated in Figure 2 . The maximal rate of lysis was obtained at a steady-state plasma u-PA antigen concentration of 0.021±0.007 ,ug/mL of rscu-PA/MA-12B3 compared with 0.011 ±0.004 ,ug/mL of rscu-PA/MA-15C5 (p=NS), with 0.46±0.05 ,ug/mL of rscu-PA (p<0.001), and with 0.031±0.006 ,ug/mL of rt-PA (p=NS).
Average plasma clearances derived from the steadystate plasma u-PA antigen levels at the end of the infusion were 0.37±0.02 mL* min-1 for rscu-PA/MA-12B3, 0.49+0.04 mL. min' for rscu-PA/MA-15C5, 1.9±0.12 mL* min-1 for rscu-PA, and 2.4±0.42 mLmin' for rt-PA (Table 5) PA/MA-15C5 (0.016 mg/kg) which gave maximal lysis within 90 minutes, is illustrated in Figure 3 . The curves were fitted with the exponentially transformed sigmoidal function as described in "Methods. To gain some insight in the parameters that determine the extent of clot lysis, its time course was measured by continuous external radioisotope scanning in the hamster model.31 '32 At doses that induced maximal clot lysis within 90 minutes, lysis with all compounds was still characterized by a lag phase of 18 minutes with rscu-PA/MA-12B3, 28 minutes with rscu-PA/MA-15C5 (p=NS versus rscu-PA/MA-12B3), and 34 minutes with rscu-PA (p=0.03 versus rscu-PA/MA-12B3). Furthermore, the maximal rates of clot lysis (slope of the time course curve at the inflection point) and the time required to reach maximal clot lysis were very similar at approximately 80 minutes for all compounds. These data indicated that although clot targeting of rscu-PA resulted in a significant reduction of the dose required to obtain maximal clot lysis, clot targeting did not result in a significant increase of the maximal rate of lysis or in a significant reduction of the lag phase before initiation of clot-lysis. Because these latter observations were surprising, the thrombolytic parameters of the two rscu-PA/antifibrin conjugates were also compared with those of rt-PA. The thrombolytic potency of rt-PA was sixfold lower than those of the rscu-PA/antifibrin conjugates but sixfold higher than that of rscu-PA. The latter finding is apparently at variance with the experience in patients with myocardial infarction, where it was shown that the therapeutic doses of rt-PA and rscu-PA are very similar.3536 However, it is well known that rodents in general are more resistant to rscu-PA than to rt-PA.37 '38 The time course of clot lysis with rt-PA, when fitted with the exponentially transformed sigmoidal function as described in "Methods," revealed a lag phase of 25+±3.9 minutes (n=4), a maximal lysis rate of 1.1±0.16% per minute, and a time to maximal clot lysis of 77±6 minutes. None of these parameters were significantly different from the corresponding parameters for rscu-PA/MA-12B3, rscu-PA/MA-15C5, and rscu-PA and did not change significantly at a fourfold higher dose of rt-PA.
Our data confirm that antibody-targeting increases the thrombolytic potency (percent lysis per unit dose administered) as well as the specific thrombolytic activity (lysis per unit steady-state plasma level) of rscu-PA, resulting in a significant reduction of its dose required for effective clot lysis. Increased specific activities could also be associated with reduced side effects, although this remains to be demonstrated.
In conclusion, the methods and models of the present study allowed the systematic evaluation of the effect of clot targeting on the extent of clot lysis, on the lag phase before the initiation of clot lysis, and on the maximal rate of clot lysis. The results suggest that clot targeting may produce more potent thrombolytic agents but that there may be a ceiling for the maximal achievable speed of clot lysis imposed by intrinsic maximal rates of lysis and minimal lag phases, which are independent of the nature of the plasminogen activator or of clot targeting.
